AcuCort has submitted a price and subsidy application to the Swedish price authority Tandvårds- och läkemedelsförmånsverket (TLV) regarding the company's drug Zeqmelit®. The application is considered to be an important milestone ahead of the market introduction of Zeqmelit® in Sweden. The application aims to give AcuCort approval for a subsidized price of the oral film Zeqmelit® in Sweden, which means that the medicine can be sold to the end consumer for a lower price and at the same time be covered by the so-called high cost protection.

As previously communicated, the application was preceded by a questionnaire study that included 426 allergy patients. The study yielded a positive outcome where, among other things, 72% of the patients answered that they would prefer an oral film to tablet treatment in the event of a severe allergic reaction. The survey study is considered by AcuCort to be an important basis for the application to TLV.